Teva Pharmaceutical Industries share price today
(NASDAQ: TEVA)

Name: Teva Pharmaceutical Industries Share Price Today (NASDAQ: TEVA) - Teva Pharmaceutical Industries Stock Price Live Quote | INDmoney
Brand: INDmoney
Rating: 4.7 (371551 reviews)

Teva Pharmaceutical Industries share price is $21.79 & ₹1,884.62 as on 24 Jan 2025, 2.30 'hrs' IST

$21.79

▲

-0.22

(-1%)

Market is closed - opens 8 PM, 24 Jan 2025

View live Teva Pharmaceutical Industries share price in Dollar and Rupees. Guide to invest in Teva Pharmaceutical Industries stock from India, including Indian investor sentiment. Get details on Indian mutual funds investing in Teva Pharmaceutical Industries, along with analyst recommendations, forecasts, and comprehensive financials.

Teva Pharmaceutical Industries share price movements

Today's Low: $21.42
Today's High: $22.10
$21.79
1.72%
Downside
Day's Volatility :3.08%
Upside
1.38%
52 Weeks Low: $11.48
52 Weeks High: $22.80
$21.79
47.32%
Downside
52 Weeks Volatility :49.65%
Upside
4.43%

Teva Pharmaceutical Industries Returns

Period	Teva Pharmaceutical Industries Ltd	Sector (Health Care)	Index (Russel 2000)
3 Months	22.96%	-4.8%	0.0%
6 Months	28.71%	-5.1%	0.0%
1 Year	86.05%	2.5%	0.0%
3 Years	158.03%	10.2%	-13.0%

Teva Pharmaceutical Industries Key Statistics

in dollars & INR

Previous Close	$22.01
Open	$22.01
Today's High	$22.095
Today's Low	$21.415
Market Capitalization	$24.7B
Today's Volume	$11.1M
52 Week High	$22.8
52 Week Low	$11.48
Revenue TTM	$16.8B
EBITDA	$4.8B
Earnings Per Share (EPS)	$-0.85
Profit Margin	-5.72%
Quarterly Earnings Growth YOY	0.4%
Return On Equity TTM	-17.52%

How to invest in Teva Pharmaceutical Industries Stock (TEVA) from India?

It is very easy for Indian residents to invest directly in Teva Pharmaceutical Industries from India. Indian investors can open a free US stocks account on the INDmoney app. You can find live prices of the Teva Pharmaceutical Industries stock in both Indian Rupees (INR) and US Dollars (USD). Search for Teva Pharmaceutical Industries or TEVA on the INDmoney app and click on Buy or SIP. You can invest by choosing quantities of shares of Teva Pharmaceutical Industries or rupee/ dollar value or set up a fixed SIP amount to be invested every month or week.

For example: You can easily buy Rs.100 worth of Teva Pharmaceutical Industries shares which would translate to 0.040 fractional shares of Teva Pharmaceutical Industries as of today. Learn more about fractional investing.

Indians can now also easily transfer and add money to their US stocks account via the INDmoney app. Invest in US Stocks from India, including recognised companies like Teva Pharmaceutical Industries, in just a few clicks!

Returns in Teva Pharmaceutical Industries for Indian investors in Rupees

Investment Value

₹1,00,000

Teva Pharmaceutical Industries investment value today

Current value as on today

₹1,88,302

Returns

₹88,302

(+88.3%)

Returns from Teva Pharmaceutical Industries Stock

₹84,193 (+84.19%)

Dollar Returns

₹4,109 (+4.11%)

Indian investors sentiment towards Teva Pharmaceutical Industries

Period: Oct 25, 2024 to Jan 23, 2025. Change in 30 Days versus previous period

Search volume for Teva Pharmaceutical Industries on INDmoney from India has grown in the last 30 days as on Jan 24, 2025. 4% more investors are searching Teva Pharmaceutical Industries in the last 30 days versus the previous period.

Global Institutional Holdings in Teva Pharmaceutical Industries

FMR Inc
5.54%
BlackRock Inc
3.87%
Ion Asset Management Ltd.
3.20%
Clal Insurance Enterprises Holdings Ltd
3.05%
MENORA MIVTACHIM HOLDINGS LIMITED
2.55%
Exor Investments (UK) LLP
2.34%

Analyst Recommendation on Teva Pharmaceutical Industries

Sell

0%Buy

33%Hold

66%Sell

Based on 9 Wall street analysts offering stock ratings for Teva Pharmaceutical Industries(by analysts ranked 0 to 5 stars)

Based on 9 analyst

Current
1M Ago
3M Ago

Buy

Hold

Sell

Analyst Forecast on Teva Pharmaceutical Industries

What analysts predicted

Upside of 14.48%

Target:

$24.95

Current:

$21.79

Insights on Teva Pharmaceutical Industries

Price Movement
In the last 1 year, TEVA stock has moved up by 83.9%
Increasing Revenue
Teva Pharmaceutical Industries Ltd has shown positive revenue growth over the last three quarters. The revenue increased from $3.83 billion to $4.33 billion, with an average increase of 5.9% each quarter.
Increasing Net Profit
Teva Pharmaceutical Industries Ltd has shown an improvement in its net profit over the last two quarters. The company's net profit increased from -$845.0 million to -$437.0 million. This translates to an average increase of 93.4% per quarter.
TEVA vs ITCI (1 yr)
In the last 1 year, Intra-cellular Therapies, Inc. has given 92.4% return, outperforming this stock by 8.5%
TEVA vs ITCI (3 yr)
In the last 3 years, Intra-cellular Therapies, Inc. has given 186.8% return, outperforming this stock by 26.6%
Price to Sales
Teva Pharmaceutical Industries Ltd has a Price-to-Sales Ratio of 1.5, meaning investors are willing to pay $1.5 for every $1 of sales the company generates. In contrast, for Intra-cellular Therapies, Inc., investors are willing to pay $20.8 for every $1 of sales. This indicates that Teva is valued significantly lower relative to its sales compared to Intra-cellular Therapies.

Teva Pharmaceutical Industries Financials in INR & Dollars

	FY18	Y/Y Change
Revenue	$18.9B	↓ 15.77%
Net Income	$-2.2B	↓ 86.78%
Net Profit Margin	-11.4%	↑ 61.26%

	FY19	Y/Y Change
Revenue	$16.9B	↓ 10.43%
Net Income	$-999.0M	↓ 53.53%
Net Profit Margin	-5.92%	↑ 5.48%

	FY20	Y/Y Change
Revenue	$16.7B	↓ 1.36%
Net Income	$-4.0B	↑ 299.4%
Net Profit Margin	-23.95%	↓ 18.03%

	FY21	Y/Y Change
Revenue	$15.9B	↓ 4.68%
Net Income	$417.0M	↓ 110.45%
Net Profit Margin	2.63%	↑ 26.58%

	FY22	Y/Y Change
Revenue	$14.9B	↓ 6.0%
Net Income	$-2.4B	↓ 664.27%
Net Profit Margin	-15.77%	↓ 18.4%

	FY23	Y/Y Change
Revenue	$15.8B	↑ 6.17%
Net Income	$-559.0M	↓ 76.24%
Net Profit Margin	-3.53%	↑ 12.24%

	Q2 FY23	Q/Q Change
Revenue	$3.9B	↑ 5.93%
Net Income	$-863.0M	↑ 320.98%
Net Profit Margin	-22.25%	↓ 16.65%

	Q3 FY23	Q/Q Change
Revenue	$3.9B	↓ 0.72%
Net Income	$80.0M	↓ 109.27%
Net Profit Margin	2.08%	↑ 24.33%

	Q4 FY23	Q/Q Change
Revenue	$4.5B	↑ 15.77%
Net Income	$429.0M	↑ 436.25%
Net Profit Margin	9.63%	↑ 7.55%

	Q1 FY24	Q/Q Change
Revenue	$3.8B	↓ 14.02%
Net Income	$-139.0M	↓ 132.4%
Net Profit Margin	-3.63%	↓ 13.26%

	Q2 FY24	Q/Q Change
Revenue	$4.2B	↑ 8.61%
Net Income	$-845.0M	↑ 507.91%
Net Profit Margin	-20.3%	↓ 16.67%

	Q3 FY24	Q/Q Change
Revenue	$4.3B	↑ 4.08%
Net Income	$-437.0M	↓ 48.28%
Net Profit Margin	-10.09%	↑ 10.21%

	FY18	Y/Y Change
Profit	$8.3B	↓ 23.36%

	FY19	Y/Y Change
Profit	$7.5B	↓ 9.16%

	FY20	Y/Y Change
Profit	$7.7B	↑ 2.51%

	FY21	Y/Y Change
Profit	$7.6B	↓ 1.7%

	FY22	Y/Y Change
Profit	$7.0B	↓ 8.18%

	FY23	Y/Y Change
Profit	$7.6B	↑ 9.64%

	Q2 FY23	Q/Q Change
Profit	$1.8B	↑ 13.53%

	Q3 FY23	Q/Q Change
Profit	$1.9B	↑ 3.06%

	Q4 FY23	Q/Q Change
Profit	$2.4B	↑ 30.52%

	Q1 FY24	Q/Q Change
Profit	$1.8B	↓ 26.16%

	Q2 FY24	Q/Q Change
Profit	$2.0B	↑ 13.34%

	Q3 FY24	Q/Q Change
Profit	$2.1B	↑ 6.23%

	FY18	Y/Y Change
Operating Cash Flow	$2.4B	↓ 30.25%
Investing Cash Flow	$1.9B	↓ 13.77%
Financing Cash Flow	$-3.4B	↓ 41.72%

	FY19	Y/Y Change
Operating Cash Flow	$538.0M	↓ 78.0%
Investing Cash Flow	$1.4B	↓ 27.38%
Financing Cash Flow	$-241.0M	↓ 92.81%

	FY20	Y/Y Change
Operating Cash Flow	$1.2B	↑ 126.02%
Investing Cash Flow	$863.0M	↓ 36.31%
Financing Cash Flow	$-1.9B	↑ 682.16%

	FY21	Y/Y Change
Operating Cash Flow	$798.0M	↓ 34.37%
Investing Cash Flow	$1.5B	↑ 76.48%
Financing Cash Flow	$-2.2B	↑ 15.23%

	FY22	Y/Y Change
Operating Cash Flow	$1.6B	↑ 99.25%
Investing Cash Flow	$656.0M	↓ 56.93%
Financing Cash Flow	$-1.5B	↓ 31.54%

	Q2 FY23	Q/Q Change
Operating Cash Flow	$324.0M	↓ 323.45%
Investing Cash Flow	$302.0M	↑ 0.0%
Financing Cash Flow	$-55.0M	↓ 92.21%

	Q3 FY23	Q/Q Change
Operating Cash Flow	$5.0M	↓ 98.46%
Investing Cash Flow	$184.0M	↓ 39.07%
Financing Cash Flow	$-576.0M	↑ 947.27%

Teva Pharmaceutical Industries Technicals Summary

Sell

Neutral

Buy

Teva Pharmaceutical Industries is currently in a neutral trading position according to technical analysis indicators.

Teva Pharmaceutical Industries Vs Peers

Company Name	1 Month	6 Month	1 Year	3 Years	5 Years
Teva Pharmaceutical Industries Ltd	-2.7%	28.71%	86.05%	158.03%	117.28%
Intra-cellular Therapies, Inc.	47.85%	58.17%	89.83%	172.62%	447.12%
Haleon Plc Spon Ads	-5.34%	-0.11%	14.11%	24.43%	24.43%
Zoetis Inc.	0.67%	-7.35%	-11.05%	-14.66%	22.56%
Neurocrine Biosciences Inc.	5.56%	-0.03%	4.08%	93.28%	48.77%
Viatris Inc.	-11.31%	-7.78%	-5.11%	-24.11%	-31.82%

Company Name	P/E Ratio	P/B Ratio	PEG Ratio	EPS	ROE	ROA	Div Yield	BVPS
Teva Pharmaceutical Industries Ltd	30.17	NA	1.23	2.48	-0.18	0.06	NA	5.35
Intra-cellular Therapies, Inc.	NA	NA	0.0	-0.7	-0.1	-0.07	NA	10.8
Haleon Plc Spon Ads	28.0	28.0	1.65	0.36	0.07	0.04	0.02	1.82
Zoetis Inc.	31.32	31.32	2.61	5.88	0.47	0.15	0.01	11.59
Neurocrine Biosciences Inc.	39.03	39.03	0.34	6.6	0.16	0.12	NA	26.87
Viatris Inc.	224.4	NA	0.07	2.69	-0.04	0.02	0.04	16.58

Company Name	Analyst View	Market Cap	5 Years Return %	PE Ratio	Profit Margin
Teva Pharmaceutical Industries Ltd	Sell	$24.7B	117.28%	30.17	-5.72%
Intra-cellular Therapies, Inc.	Buy	$13.4B	447.12%	NA	-14.07%
Haleon Plc Spon Ads	Buy	$41.8B	24.43%	28.0	10.75%
Zoetis Inc.	Buy	$75.2B	22.56%	31.32	26.55%
Neurocrine Biosciences Inc.	Buy	$14.9B	48.77%	39.03	17.21%
Viatris Inc.	Hold	$13.5B	-31.82%	224.4	-5.87%

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; GRANIX; TRISENOX; LONQUEX; and TEVAGRASTIM/RATIOGRASTIM. In addition, it provides COPAXONE for the treatment of relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO for the treatment of neurodegenerative and movement disorders associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR for treatment for asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax, an inhaled corticosteroid and long-acting beta-agonist bronchodilator; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv, Israel.

Organization	Teva Pharmaceutical Industries
Employees	37000
CEO	Mr. Richard D. Francis
Industry	Health Technology

Management People of Teva Pharmaceutical Industries

Name	Title
Mr. Richard D. Francis	President, CEO & Director
Mr. Eliyahu Sharon Kalif	Executive VP & CFO
Mr. Mark Sabag	Executive Vice President of International Markets Commercial
Mr. Richard Gordon Daniell	Executive Vice President of European Commercial
Mr. Matthew Shields	Executive Vice President of Global Operations
Mr. Amir Weiss	Senior VP & Chief Accounting Officer
Mr. Christopher J. Stevo CFA	Senior Vice President of Investor Relations & Competitive Intelligence
Kathleen Veit	Senior Vice President, Global Compliance & Ethics Officer
Mr. David R. Mcavoy J.D.	Executive VP & Chief Legal Officer
Mr. Placid Jover	Executive VP & CHRO

Important FAQs about investing in Teva Pharmaceutical Industries (TEVA) from India :

What is Teva Pharmaceutical Industries share price today?

Teva Pharmaceutical Industries share price today stands at $21.79, Open: $22.01 ; Previous Close: $22.01 ; High: $22.10 ; Low: $21.42 ; 52 Week High: $22.80 ; 52 Week Low: $11.48. The stock opens at $22.01, after a previous close of $22.01. The stock reached a daily high of $22.10 and a low of $21.42, with a 52-week high of $22.80 and a 52-week low of $11.48.

Can Indians buy Teva Pharmaceutical Industries shares?

Yes, Indians can invest in the Teva Pharmaceutical Industries (TEVA) from India.

With INDmoney, you can buy Teva Pharmaceutical Industries at 0 brokerage. The step-by-step process is as follows:

Open your zero cost US Stocks account and zero balance IND linked savings a/c (this can be done in less than 3 minutes)
Transfer funds to your US Stocks account using your IND linked savings a/c (It takes 24 hours excluding Saturday and Sunday). With INDmoney, you get the best INR USD exchange rates.
Once funds are transferred successfully, you can buy Teva Pharmaceutical Industries at zero transaction cost.

How can I buy Teva Pharmaceutical Industries shares from India?

It is very easy to buy Teva Pharmaceutical Industries from India. With INDmoney, you can open a US stocks account in less than 3 minutes. Transfer funds in 24 hours and buy stocks very easily - that too at 0 brokerage. All this is done at 0 account opening & management fee, 0 brokerages, and at the same time you get the best rupee-US dollar exchange rate.

Can Fractional shares of Teva Pharmaceutical Industries be purchased?

Yes, you can buy fractional shares of Teva Pharmaceutical Industries with INDmoney app.

What are the documents required to start investing in Teva Pharmaceutical Industries stocks?

To start investing in Teva Pharmaceutical Industries, You will need the following documents:

Proof of Identification (PAN, Aadhaar etc)
Proof of address (Aadhaar, Voter ID etc)

These documents are required as per RBI's guidelines to create your IND linked savings a/c so that you can execute for global fund transfer. The entire process is paperless and can be completed seamlessly.